Pipeline

Astex Pharmaceuticals™ has established a strong pipeline of small molecule, molecularly targeted drugs. SGI-110 and AT13387 are prioritized and advancing in multiple, potential indications.

Program / Mechanism / Indication

Phase 1

Phase 2

Phase 3

Marketed

Partner

DACOGEN® – Hypomethylator (MDS)
  • Eisai
  • Janssen
DACOGEN® – Hypomethylator (Elderly AML)
  • Eisai
  • Janssen
AT13387 – HSP90 inhibitor (GIST, Prostate & Lung)
  •  
SGI110 – DNMT inhibitor (MDS, AML, Ovarian & Liver)
  •  
Amuvatinib/MP470 (SCLC)
  •  
AT7519 – CDK inhibitor (MM)
  • Novartis
*
AT9283 – JAK/Aurora inhibitor (MM)
  •  
AT13148 – AGC kinase inhibitor
  • Cancer Research Technology
  • The Institute of Cancer Research
* Optioned.
Priority Product

Partnered Products and Programs

Astex’s partners are advancing several Astex compounds in phase 1 clinical trials. These trials are completely funded and executed by our partners.

Compound Name / Mechanism

Discovery

Preclinical

Phase 1

Phase 2

Partner

LEE011 – CDK4 inhibitor (Oncology)
  • Novartis
AZD5363 – PKB/Akt inhibitor (Oncology)
  • AstraZeneca
JNJ42756493 - FGFr inhibitor (Oncology)
  • Janssen
AZD3293 – BACE inhibitor (Alzheimer’s)
  • AstraZeneca
Discovery milestones achieved
Multiple targets (Multiple therapeutic areas)
  • gsk